Trident Brands (TDNT) 10-K 14 Apr 22 2021 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Nov. 30, 2021	Mar. 15, 2022
Cover [Abstract]
Entity Registrant Name	TRIDENT BRANDS INCORPORATED
Entity Central Index Key	0001421907
Document Type	10-K
Amendment Flag	false
Entity Voluntary Filers	No
Current Fiscal Year End Date	--11-30
Entity Well Known Seasoned Issuer	No
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Current Reporting Status	Yes
Document Period End Date	Nov. 30, 2021
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Entity Ex Transition Period	false
Entity Common Stock Shares Outstanding		33,311,887
Entity Public Float	$ 1,065,980
Document Annual Report	true
Document Transition Report	false
Entity File Number	000-53707
Entity Incorporation State Country Code	NV
Entity Tax Identification Number	26-1367322
Entity Address Address Line 1	433 Plaza Real
Entity Address Address Line 2	Suite 275
Entity Address City Or Town	Boca Raton
Entity Address State Or Province	FL
Entity Address Postal Zip Code	33432
City Area Code	561
Auditor Name	MaloneBailey, LLP
Auditor Location	Houston, Texas
Local Phone Number	962-4122
Security 12g Title	Common Stock, $.001 par value
Entity Interactive Data Current	Yes
Auditor Firm Id	206

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Nov. 30, 2021	Nov. 30, 2020
Current Assets
Cash and Cash Equivalents	$ 7,653	$ 88,007
Accounts Receivable, net of allowance for doubtful accounts of $160,210 and $155,186, respectively	12,358	63,784
Inventory, net of reserves of $401,606 and $195,264, respectively	881,924	1,219,567
Prepaid and other current assets	158,146	155,179
Total Current Assets	1,060,081	1,526,537
Fixed Assets-Furniture & Fixtures, net	0	0
Intangible Assets	0	400,000
TOTAL ASSETS	1,060,081	1,926,537
Current Liabilities
Accounts Payable	524,207	429,009
Accrued Liabilities	9,405,833	7,480,846
Total Current Liabilities	9,930,040	7,909,855
PPP Loan Payable	0	135,165
Convertible Debt, net of discount of $0 and $0 respectively	22,300,000	22,300,000
Total Liabilities	32,230,040	30,345,020
Stockholders' Deficit
Common stock, $0.001 par value, 300,000,000 shares authorized; 33,311,887 shares issued and outstanding as of November 30, 2021 and 32,311,887 as of November 30, 2020	33,312	32,312
Additional paid-in capital	11,492,630	11,458,630
Non-Controlling Interest in Subsidiary	(490,852)	(387,147)
Accumulated Deficit	(42,205,049)	(39,522,278)
Total Stockholders' Deficit	(31,169,959)	(28,418,483)
TOTAL LIABILITIES & STOCKHOLDERS' DEFICIT	$ 1,060,081	$ 1,926,537

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Nov. 30, 2021	Nov. 30, 2020
Consolidated Balance Sheets
Allowances for account receivable	$ 160,210	$ 155,186
Inventory, net of reserves	401,606	195,264
Debt discount, convertible debt non-current	$ 0	$ 0
Common stock, shares par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	33,311,887	33,311,887
Common stock, shares outstanding	33,311,887	33,311,887

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Nov. 30, 2021	Nov. 30, 2020
Consolidated Statements of Operations
Revenues, net	$ 224,720	$ 872,923
Cost of Sales	121,047	628,801
Gross Profit	103,673	244,122
General & Administrative Expenses	(2,126,544)	(4,571,077)
Impairment Loss	(400,000)	0
Loss from Operations	(2,422,871)	(4,326,955)
Other Income (Expenses)
Interest Expense, net	(798,770)	(4,298,280)
Gain on Debt Forgiveness	135,165	10,000
Loss on Debt Extinguishment	0	(1,092,295)
Derivative gain (loss)	0	4,312,338
Total Other Income (Expenses)	(663,605)	(1,068,237)
Net Loss	(3,086,476)	(5,395,192)
Net loss attributable to Trident	(2,682,771)	(5,296,648)
Net loss attributable to Non-Controlling Interests	$ (403,705)	$ (98,544)
Loss per share - Basic and diluted	$ (0.08)	$ (0.16)
Weighted average number of common shares outstanding - Basic and diluted	32,314,627	32,311,887

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Deficit - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Non- Controlling Interest [Member]
Balance, shares at Nov. 30, 2019		32,311,887
Balance, amount at Nov. 30, 2019	$ (24,536,433)	$ 32,312	$ 9,945,488	$ (34,225,630)	$ (288,603)
APIC reclassified to derivative liability	(3,981,221)	0	(3,981,221)	0	0
Resolution of derivative liability	5,494,363		5,494,363
Net loss, November 30, 2020	(5,395,192)	$ 0	0	(5,296,648)	(98,544)
Balance, shares at Nov. 30, 2020		32,311,887
Balance, amount at Nov. 30, 2020	(28,418,483)	$ 32,312	11,458,630	(39,522,278)	(387,147)
Net loss, November 30, 2020	(3,086,476)	$ 0	0	(2,682,770)	(403,705)
Issuance of Common Shares for services, shares		1,000,000
Issuance of Common Shares for services, amount	35,000	$ 1,000	34,000	0	0
NCI Investment in Brain Armor	300,000	$ 0	0	0	300,000
Balance, shares at Nov. 30, 2021		33,311,887
Balance, amount at Nov. 30, 2021	$ (31,169,959)	$ 33,312	$ 11,492,630	$ (42,205,049)	$ (490,852)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Nov. 30, 2021	Nov. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (3,086,476)	$ (5,395,192)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount	0	1,885,587
Loss on debt extinguishment	0	1,092,295
Depreciation expense	0	4,413
Impairment Loss	400,000	0
Inventory write-off	206,342	195,264
Gain on Note Payable Forgiveness	(135,165)
Derivative (gain)/loss		(4,312,338)
Issuance of common shares for services	35,000
Provision for bad debts	5,024	99,207
Changes in operating assets and liabilities:
Accounts receivable	46,402	117,356
Prepaid expenses	(2,966)	13,148
Inventory	131,301	667,995
Accounts payable and accrued liabilities	2,020,186	3,635,265
Cash used in operating activities	(380,354)	(1,997,000)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from PPP loan	0	135,165
Proceeds from convertible debt	0	936,168
Proceeds from NCI Investment in Brain Armor	300,000	0
Cash provided by financing activities	300,000	1,071,333
NET CHANGE IN CASH AND CASH EQUIVALENTS	(80,354)	(925,667)
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	88,007	1,013,674
CASH AND CASH EQUIVALENTS AT END OF YEAR	7,653	88,007
Supplemental disclosure of cash flow information:
Income taxes	0	0
Interest	$ 0	$ 0

ORGANIZATION AND DESCRIPTION OF

ORGANIZATION AND DESCRIPTION OF BUSINESS	12 Months Ended
	Nov. 30, 2021
ORGANIZATION AND DESCRIPTION OF BUSINESS
ORGANIZATION AND DESCRIPTION OF BUSINESS	NOTE 1. ORGANIZATION AND DESCRIPTION OF BUSINESS Trident Brands Incorporated (“we”, “our”, “the Company”) was incorporated under the laws of the State of Nevada on November 5, 2007. The Company is focused on the development of high growth branded consumer products and ingredients within the nutritional supplement, life sciences and food and beverage categories. The Company is in its early growth stage and has transitioned out of its shell status with the “Super-8-K” filing at the end of August, 2014. Activities to date have focused on capital formation, organizational development and execution of its branded consumer products and ingredients business plan.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Nov. 30, 2021
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Accounting The Company’s financial statements are prepared using the accrual method of accounting. The Company has elected a November 30 year-end. Use of Estimates and Assumptions The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The ultimate impact from COVID-19 on the Company’s operations and financial results during 2021 and beyond will depend on, among other things, the ultimate severity and scope of the pandemic, the pace at which governmental and private travel restrictions and public concerns about public gatherings will ease, the rate at which historically large increases in unemployment rates will decrease, if at all, and whether, and the speed with which the economy recovers. We are not able to fully quantify the impact that these factors will have on our financial results in 2022 and beyond, but developments related to COVID-19 materially and adversely affected the Company’s financial performance in 2021. Principles of Consolidation The Company’s consolidated financial statements as of November 30, 2021 include the accounts of Trident Brands Incorporated and its subsidiaries: Brain Armor Inc. and Trident Brands Canada Ltd. Earnings (Loss) Per Share The Company follows the guidance in ASC No. 260, “Earnings Per Share”, which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. Basic net earnings (loss) per share amounts are computed by dividing the net earnings (loss) by the weighted average number of common shares outstanding. Due to net losses during the years ended November 30, 2021 and 2020, diluted earnings (loss) per share are the same as the basic earnings (loss) per share since inclusion of common stock equivalents would have been anti-dilutive. Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Accounts Receivable and Allowance for Doubtful Accounts Accounts receivables are recorded at their original invoice amounts. We regularly review collectability and establish an allowance for uncollectible amounts as necessary. As of November 30, 2021 and 2020, the Company’s accounts receivable was netted against an allowance of $160,210 and $155,186 respectively. Inventory Inventories are stated at the lower of cost or net realizable value. Cost is principally determined using the first-in, first-out (FIFO) method. We regularly review inventory for obsolete and slow-moving inventory and recognize a reserve or write offs as necessary. We recognized an inventory reserve of $401,606 and $195,264 as of November 30, 2021 and 2020, respectively. Inventory at November 30, 2021 consist of raw materials and finished goods of $842,076 and 39,848 respectively. Inventory at November 30, 2020 consist of raw materials and finished goods of $842,076 and $377,491, respectively. Long-Lived Assets We review our long-lived assets, including intangible assets subject to amortization, for recoverability whenever events or changes in circumstances indicate that the carrying amount of such long-lived asset or group of long-lived assets (collectively referred to as “the asset”) may not be recoverable. Such circumstances include, but are not limited to: · a significant decrease in the market price of the asset; · a significant change in the extent or manner in which the asset is being used; · a significant change in the business climate that could affect the value of the asset; · a current period loss combined with projection of continuing loss associated with use of the asset; and · a current expectation that, more likely than not, the asset will be sold or otherwise disposed of before the end of its previously estimated useful life. We continually evaluate whether such events and circumstances have occurred. When such events or circumstances exist, the recoverability of the asset’s carrying value shall be determined by estimating the undiscounted future cash flows (cash inflows less associated cash outflows) that are directly associated with and that are expected to arise as a direct result of the use and eventual disposition of the asset. Intangible Assets Intangible assets have either an identifiable or indefinite useful life. Intangible assets with identifiable useful lives are amortized on a straight-line basis over their economic or legal life, whichever is shorter. The Company currently does not have any amortizable intangible assets. The Company’s indefinite-lived intangible assets consist of trademarks. The Company reviews its indefinite-lived intangible assets for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. Impairment losses are recognized only if the carrying amount exceeds its fair value. Beneficial Conversion Features The intrinsic value of a beneficial conversion feature inherent to a convertible note payable, which is not bifurcated and accounted for separately from the convertible note payable and may not be settled in cash upon conversion, is treated as a discount to the convertible note payable. This discount is amortized over the period from the date of issuance to the date the note is due using the effective interest method. If the note payable is retired prior to the end of its contractual term, the unamortized discount is expensed in the period of retirement to interest expense. In general, the beneficial conversion feature is measured by comparing the effective conversion price, after considering the relative fair value of detachable instruments included in the financing transaction, if any, to the fair value of the common shares at the commitment date to be received upon conversion. Fair Value of Financial Instruments The Company measures its financial assets and liabilities in accordance with the requirements of FASB ASC 820, “Fair Value Measurements and Disclosures”. ASC 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows: Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed equities. Level 2 - Pricing inputs are other than quoted prices in active markets included in level 1, which are either directly or indirectly observable as of the reported date and includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors, and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options and collars. Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value. The carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash and cash equivalents, accounts receivable, accounts payable and note payable. The fair value of the Company’s long-term debt is estimated based on current rates that would be available for debt of similar terms which is not significantly different from its stated value. As of November 30, 2021 the Company did not have any financial assets or liabilities measured and recorded at fair value on the Company’s consolidated balance sheets on a recurring basis, except for a derivative liability, related to the embedded conversion option on the 2016 and 2018 convertible notes, with a fair value of $0 as of November 30, 2021 and 2020. The derivative liability was fair valued using Level 3 inputs. The following table provides a summary of the changes in fair value, including net transfers in and/or out, of the derivative financial instruments, measured at fair value on a recurring basis using significant unobservable inputs: Balance at November 30, 2019 5,825,480 Unrealized derivative gain included in other expense (4,312,338 ) APIC reclassified to derivative liability 3,981,221 Resolution of derivative liability (5,494,363 ) Balance at November 30, 2020 and 2021 $ -0- The fair value of the derivative liabilities are calculated at the time of issuance and the Company records a derivative liability for the calculated value. Changes in the fair value of the derivative liabilities are recorded in other income (expense) in the consolidated statements of operations. The following are the assumptions used for derivative instruments valued using the Black Scholes option pricing model as of November 30, 2021 and November 30, 2020: 2021 2020 Market value of stock on measurement date $ N/A $ 0.033 Risk-fee interest rate N/A 0.16% and 0.18 % Dividend yield N/A 0 % Volatility factor N/A 173.23 % Term. N/A 0.085 and 1.0 yrs Derivative Financial Instruments Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments and measurement of their fair value for accounting purposes. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt under ASC 470, the Company will continue its evaluation process of these instruments as derivative financial instruments under ASC 815. The Company applies the guidance in ASC 815-40-35-12 to determine the order in which each convertible instrument would be evaluated for derivative classification. The Company’s sequencing policy is to evaluate for reclassification contracts with the earliest inception date first. Revenue The Company markets a range of branded consumer products in the active nutrition and dietary supplement categories under the Brain Armor® label. Four customers accounted for 18.9%, 16.8%, 14.4% and 12.4% of total revenue, compared to four customers for 22.3%, 17.7%, 13.0% and 10.2% in the prior year. One customer accounted for 10.9% of total accounts receivable, compared to three customers for 16.9%, 15.9% and 11.9% in the prior year. The Company records revenue when all of the following criteria are met: 1) the contract with a customer is identified, 2) the performance obligations in the contract are identified, 3) the transaction price is determined, 4) the transaction price has been allocated to the performance obligations and 5) when each performance obligation is satisfied. Customer returns, allowances and consideration paid to customers for services which are not considered distinct are recorded as reductions to revenues. Cost of Sales Cost of sales includes the direct purchase cost of the product based on the FIFO method. The Company purchased 100% of its products from one vendor for the year ended November 30, 2021 and three vendors provided 97% of the Company’s products for the year ended November 30, 2020. Stock-Based Compensation The Company accounts for employee and non-employee stock-based compensation in accordance with ASC-718, “Compensation-Stock Compensation”. ASC-718 requires companies to measure the cost of employee services received in exchange for an award of equity instruments, including stock options, based on the grant-date fair value of the award and to recognize it as compensation expense over the period the employee is required to provide service in exchange for the award, usually the vesting period. Income Taxes Income taxes are provided in accordance with ASC No. 740, Accounting for Income Taxes. A deferred tax asset or liability is recorded for all temporary differences between financial and tax reporting and net operating loss carryforwards. Deferred tax expense (benefit) results from the net change during the year of deferred tax assets and liabilities. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion of all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The Company includes interest and penalties arising from the underpayment of income taxes in the statements of operation in the provision for income taxes. As of November 30, 2021 and 2020, the Company had no accrued interest or penalties related to uncertain tax positions. Related Parties A party is considered to be related to the Company if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests is also a related party. On October 15, 2021, a Promissory Note was issued to Anthony Pallante, Chairman and a significant stockholder of the Company. The Note is unsecured and was issued in consideration for payments made to creditors in satisfaction of Company obligations. Mr. Pallante loaned the Company $20,101. The Note bears Interest at a rate of 8% per annum. All unpaid principal and accrued interest shall be due and payable upon demand at any time subsequent to six (6) months from the date the notes were issued. As of November 30, 2021, Mr. Pallante made additional payments of $16,731 for a total of $36,832. Recent Accounting Pronouncements The Company has evaluated the following recent accounting pronouncements through the date the financial statements were issued and filed with the Securities and Exchange Commission and believe that none of them will have a material effect on the Company’s financial statements: In July 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. For all other entities, the amendments in Part I of this Update are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. Management’s evaluation was that there was no impact to the Company’s consolidated financial statements. In December 2018, the FASB issued ASC 842 and as ASU 2016-02, is the new lease accounting standard published by the Financial Accounting Standards Board (FASB). It replaced the previous US GAAP leasing standard, ASC 840. The purpose of the new standard is to close a major accounting loophole in ASC 840: off-balance sheet operating leases. Public companies began to implement the standard starting after December 15, 2018. Private companies will follow a year later on December 15, 2020. ASC 842 represents a significant overhaul of the accounting treatment for leases, with the most significant change being that most leases, including most operating leases, are now capitalized on the balance sheet. Under ASC 840, FASB permitted operating leases to be reported only in the footnotes of corporate financial statements. Under ASC 842, the only leases that are exempt from the capitalization requirement are short-term leases less than or equal to 12 months in length. This became effective December 1, 2019 and the Company chose to adopt it early on December 1, 2018. The adoption did not have any material impact on the Company’s consolidated financial statements as the Company has no long term leases. On June 20, 2018, the FASB issued ASU 2018-07, Improvements to Nonemployee Share-Based Payment Accounting, as part of its ongoing Simplification Initiative. Currently, share-based payments to nonemployees are accounted for under Subtopic 505-50 which significantly differs from the guidance for share-based payments to employees under Topic 718. This ASU supersedes Subtopic 505-50 by expanding the scope of Topic 718 to include nonemployee awards and generally aligning the accounting for nonemployee awards with the accounting for employee awards (with limited exceptions). The effective date is for fiscal years beginning after December 15, 2018. The Company adopted the measure on December 1, 2019. The adoption did not have any material impact on the Company’s consolidated financial statements.

GOING CONCERN

GOING CONCERN	12 Months Ended
	Nov. 30, 2021
GOING CONCERN
GOING CONCERN	NOTE 3. GOING CONCERN The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business within one year after the date the consolidated financial statements are issued. In accordance with Financial Accounting Standards Board, or the FASB, Accounting Standards Update No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40), our management evaluates whether there are conditions or events, considered in aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the financial statements are issued. As of November 30, 2021, the Company had $7,653 in cash and a working capital deficit of $8,869,959. The Company also has generated losses and has an accumulated deficit as of November 30, 2021. These factors raise substantial doubt about the ability of the Company to continue as a going concern. Unless management is able to obtain additional financing, the Company may not be able to meet its funding requirements during the next 12 months. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

NOTE RECEIVABLE

NOTE RECEIVABLE	12 Months Ended
	Nov. 30, 2021
NOTE RECEIVABLE
NOTE RECEIVABLE	NOTE 4. NOTE RECEIVABLE On September 12, 2017 the Company entered into a note purchase agreement with Fengate Trident LP (“Fengate”) pursuant to which, in consideration for the issuance of 811,887 of our common shares to Fengate, we purchased outstanding secured convertible promissory notes of Mycell Technologies LLC having an aggregate balance due and payable of $511,141 in principal and $94,526 in interest accrued as at September 12, 2017. The purchased notes, which were originally issued to LPF (MCTECH) Investment Corp. on January 22, 2016, February 5, 2016, and May 19, 2016, bear simple interest on unpaid principal at the rate of ten percent per annum. The outstanding principal and accrued interest is convertible at the option of the note holder into securities of Mycell. The accrued interest as at November 30, 2018 is $105,869. The Company reserved a full allowance on the note receivable and accrued interest of $617,010 as of November 30, 2021 and November 30, 2020. Mycell filed for bankruptcy on November 25, 2020. The bankruptcy is completed and the Company no longer has a claim on the new company that has since emerged from bankruptcy.

INTANGIBLE ASSETS

INTANGIBLE ASSETS	12 Months Ended
	Nov. 30, 2021
INTANGIBLE ASSETS
INTANGIBLE ASSETS	NOTE 5. INTANGIBLE ASSETS On December 22, 2017, Trident exercised its option under our Exclusive License Agreement (dated March 1, 2015) to purchase the Brain Armor® brand from DSM Nutrition Products LLC (“DSM”). Subsequently, the parties have executed applicable trademark assignment and purchase agreements necessary to transfer all global intellectual property rights in the Brain Armor brand to Trident. In lieu of a $400,000 cash payment to DSM for the value of the Brain Armor® brand as initially intended, the Company agreed to meet certain conditions, that when satisfied will have an equivalent value of $400,000. The costs incurred to meet these conditions are being charged to intangible assets. As of November 30, 2021 and 2020, the Company has recorded $400,000 of costs to the asset account. Of this amount $200,000 is paid over time as the Company purchases omega-3 oil from DSM pursuant to its exclusive supply agreement. During the 12 months ended November 30, 2021 and 2020, no payments were made to DSM in connection with this liability. The amount outstanding as of November 30,2021 is $79,040 The Company reviewed the intangible asset for impairment and booked an impairment charge of $400,000 for the full value of the asset on November 30, 2021.

WARRANTS AND OPTIONS

WARRANTS AND OPTIONS	12 Months Ended
	Nov. 30, 2021
WARRANTS AND OPTIONS
WARRANTS AND OPTIONS	NOTE 6. WARRANTS AND OPTIONS On December 6, 2017, our Board of Directors authorized the issuance to its members and management stock options to purchase up to 2,615,000 shares of our common stock. 1,307,500 of the options vest upon issuance and are exercisable for up to five years at $0.85 per share, while the remaining 1,307,500 will vest 12 months following issuance and be exercisable for up to five years at $1.00 per share. The options were issued pursuant to the Company’s 2013 Stock Option Plan, which was registered with the Securities and Exchange Commission on Form S-8 in January, 2015. The 2013 Stock Option Plan authorizes the Company to issue incentive and non-qualified stock options to employees and consultants of the Company to purchase a number of shares not to exceed 15% of the Company’s currently issued and outstanding securities. On January 4, 2019, our Board of Directors approved the re-pricing of the majority of options previously granted at $0.40 per share. On May 5, 2019, our Board of Directors approved the extension of 750,000 previously issued and outstanding stock options originally issued on May 5, 2014 to certain individuals for an additional year to May 5, 2020. The total outstanding stock options as of November 30, 2021 are 1,832,500. For the period ended November 30, 2021, the Company expensed $0 as compensation expense compared to $8,875 in the comparable prior year period for stock options granted on December 6, 2017. The following table represents stock option activity as of and for the years ended November 30, 2021 and 2020: Number of Options Weighted Average Exercise Price Contractual Life in Years Intrinsic Value Outstanding - November 30, 2019 3,215,000 $ .40 2.42 $ -0- Exercisable - November 30, 2019 3,215,000 $ .40 2.42 Granted -0- Exercised or Vested -0- Forfeited or Expired 1,382,500 Outstanding – November 30, 2020 1,832,500 $ 0.40 2.02 Exercisable - November 30, 2020 1,832,500 $ 0.40 2.02 -0- Granted -0- Exercised or Vested -0- Forfeited or Expired 300,000 Outstanding - November 30, 2021 1,532,500 $ 0.40 1.02 Exercisable - November 30, 2021 1,532,500 $ 0.40 1.02 -0- As of November 30, 2021, the Company has no outstanding warrants. All the outstanding warrants have expired.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Nov. 30, 2021
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS	NOTE 7. RELATED PARTY TRANSACTIONS On October 15, 2021, a Promissory Note was issued to Anthony Pallante, Chairman and a significant stockholder of the Company. The Note is unsecured and was issued in consideration for payments made to creditors in satisfaction of Company obligations. Mr. Pallante loaned the Company $20,101. The Note bears Interest at a rate of 8% per annum. All unpaid principal and accrued interest shall be due and payable upon demand at any time subsequent to six (6) months from the date the notes were issued. As of November 30, 2021, Mr. Pallante made additional payments of $16,731 for a total of $36,832.

CONVERTIBLE DEBT

CONVERTIBLE DEBT	12 Months Ended
	Nov. 30, 2021
CONVERTIBLE DEBT
CONVERTIBLE DEBT	NOTE 8. CONVERTIBLE DEBT On January 29, 2015, the Company entered into a securities purchase agreement with a non-US institutional investor whereby it agreed to sell an aggregate principal amount of $2,300,000 of senior secured convertible debentures, convertible into shares of the Company’s common stock. The Company received $1,800,000 of the funds from the transaction on February 5, 2015. The balance of $500,000 was received on May 14, 2015. These convertible notes were subsequently acquired by Fengate Trident, LP (“Fengate”) on April 28, 2017. The convertible debentures are convertible into shares of the Company’s common stock at an initial conversion price of $0.71 per share, for an aggregate of up to 3,239,437 shares. The debentures originally accrued interest at 6% per annum. On September 26, 2016 the Company entered into an amendment agreement related to these convertible debentures whereby the applicable interest rate was increased from 6% to 8% and provisions added to allow the investor to transfer, sell or hypothecate the convertible notes subject to applicable securities laws. The maturity date of the notes was also extended through September 30, 2019. We considered ASC Topic 470-50, Debt Modifications and Extinguishments, and determined that the modification was not deemed substantial. Due to the note being convertible to common shares of the Company, a beneficial conversion feature analysis was performed. The intrinsic value of the conversion feature was $647,888 which was recognized as debt discount. As of November 30, 2017, the full amount of the debt discount has been amortized. On September 26, 2016, the Company entered into a securities purchase agreement with a non-US institutional investor, pursuant to which, in consideration for proceeds of $4,100,000, the Company issued a secured convertible promissory note in the amount of $4,100,000. Pursuant to the securities purchase agreement, the investor has agreed, from time to time after January 1, 2017, to make additional investments at the Company’s request of up to $5,900,000. On May 9, 2017, the Company received the second tranche of funding with proceeds of $4,400,000 and on May 16, 2018 the third tranche of $1,500,000 for a total investment by the investor of $10,000,000. In consideration of each advance made by the investor pursuant to the securities purchase agreement, the Company issued to the investor a convertible promissory note of equal value, maturing on September 30, 2019, and bearing interest at the rate of 8% per annum. Each note was secured in first priority against the present and after acquired assets of the Company and was convertible in whole or in part at the option of the holder into common shares of the Company at a conversion price of $0.60 per share, for an aggregate of up to 16,666,667 shares. These convertible notes were subsequently acquired by Fengate on April 28, 2017. Due to the notes being convertible to common shares of the Company, a beneficial conversion feature analysis was performed. The intrinsic value of the conversion feature of the notes amounted to $3,333,334 and was recognized as a debt discount. As of November 30, 2021, $3,333,334 of the debt discount was amortized to interest of which $334,988 was amortized during the current year compared to $855,987 in the prior year. As of November 30, 2021, the debt discount was fully amortized. On November 30, 2018 the Company and Fengate entered into a Securities Purchase Amendment Agreement (“SPA”) pursuant to which the Company has agreed to issue to Fengate additional convertible promissory notes (collectively, the “2018 and 2019 Convertible Notes”) of up to $10,000,000, subject to certain terms and conditions. Each portion of the principal amount advanced pursuant to the SPA bore interest at the rate of twelve percent (12%) per annum and was payable monthly in arrears to Fengate. Outstanding principal and interest will continue to be secured by the general security agreement dated September 26, 2016, which forms a part of the Agreement. The holder of the note may also elect from time to time to convert all or a portion of the outstanding principal and interest into common shares of the Company at a 25% discount to the average closing price of the common shares during the 10 trading days immediately prior to the applicable conversion date. The 2018 and 2019 Convertible Notes (aka “Amended SPA Notes”) were extended until December 1, 2021. The Maturity Date of the Amended SPA Notes was extended to November 30, 2025, as described below. On November 30, 2018 the Company received the first tranche of funding with proceeds of $3,400,780. The 2nd tranche of $2,804,187 was received on April 13, 2019. The 3rd tranche of $3,795,033 less $936,168 withheld for interest payments up to and including June 30, 2020 was received on November 6, 2019. On March 5, 2020, the 2018 and 2019 Convertible Notes were amended to increase the amount of the 3rd tranche by $936,168 representing the amount previously withheld as interest payment. The withheld interest was subsequently received on March 12, 2020. The Company analyzed the embedded conversion option on the convertible notes for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the conversion option on the 2018 Convertible Note qualified for derivative accounting. The Company used the Black-Scholes model to value the embedded conversion option at $892,000 on the issuance date of November 30, 2018, $1,911,256 on the issuance date of April 13, 2019 and $1,696,933 on the issuance date of November 6, 2019. The assumptions used were a discount rate of 2.80%, 1.96% and 1.96%; volatility rate of 79.57%, 104.70% and 107.3%; and a term of 1.50, 1.13 and 0.57 years respectively. The fair values of the embedded conversion options were recorded as debt discount and were amortized over the term of the 2018 and 2019 Convertible Notes. Amortization of debt discount for the years ended November 30, 2021 and 2020 was $1,885,587 and $1,857,295, respectively. The unamortized discount as of November 30, 2021 is $0. On January 9, 2020 the Company and Fengate entered into an Amendment to Convertible Promissory Notes Agreement to amend the terms of the convertible notes issued on February 5, 2015 (US$1,800,000), May 14, 2015 (US$500,000), September 26, 2016 (US$4,100,000), May 9, 2017 (US$4,400,000) and May 16, 2018 (US$1,500,000) (collectively the “2016 Convertible Notes”). Pursuant to the Amendment, Fengate has agreed to convert all of the 2016 Notes on or before the earlier to occur of (i) the maturity date of the 2016 Convertible Notes and (ii) the Company raising new equity investment of not less than US$2,000,000, on terms mutually acceptable to Fengate and the Company (subject to Fengate’s regulatory considerations). Conversion of the 2016 Notes will occur in a single conversion transaction at a price that is equal to a 25% discount to the average closing price of the Company’s common stock for the 10 trading days immediately prior to the conversion date, with the exact structure of the conversion to be determined by the parties. On June 3, 2020 the maturity date was extended from May 31 to December 31, 2020. The Amendment also extended the maturity date of the 2018 and 2019 Convertible Notes to December 1, 2021. The Company analyzed the embedded conversion option on the amended “2016 Convertible Notes” for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the conversion option qualified for derivative accounting. On January 9, 2020 the Company used the Black-Scholes model to value the embedded conversion options at $7,965,083. The assumptions used were a discount rate of 1.96%, volatility rate of 148.8%; and a term of 0.39 years respectively. The modification resulted in $3,981,221 of APIC previously recorded for beneficial conversion feature of these convertible notes being reclassified as derivative liability. On November 30, 2020, the Company entered into a fourth amendment of the 2016 Convertible Notes and the 2018 and 2019 Convertible Notes wherein the Company will issue to Fengate 29,432,320 shares of Company Preferred Stock (representing $17,659,392 of principal and interest converted into Preferred Stock at the rate of $0.60 per share), in full and complete satisfaction of (i) all amounts owing under the 2016 Convertible Notes through November 30, 2021 (including accrued interest thereon) and (ii) all accrued interest on the 2018 and 2019 Convertible Notes through November 30, 2021. The conversion is expected to occur by the end of June, 2021. The 2018 and 2019 Convertible Notes were further amended to (i) eliminate the conversion feature of such notes, (ii) provide for a simple interest rate of 8% per annum, with the first 2 years of interest payable at maturity of the 2018 and 2019 Convertible Notes and the last three years of interest payable quarterly beginning February 28, 2023; and (iii) extend the maturity of such notes until November 30, 2025. Pursuant to this amendment, all notes no longer qualified for derivative accounting. As such, the value of the embedded conversion options of all notes of $5,494,363 was credited to additional paid in capital. The consummation of the foregoing transaction is subject to (i) authorization and issuance of the Preferred Stock, which is subject to approval of the requisite number of common shares of the Company, in accordance with Nevada law and the Company’s organizational documents, and (ii) Note Holder’s obligation to remain in compliance with regulations governing its ownership of voting shares. The Company and Note Holder had previously undertaken to consummate the foregoing transactions no later than June 30, 2021. On March 29, 2022, the Board of Directors approved an amendment to our Certificate of Incorporation which authorizes 29,432,320 shares of Company Preferred Stock. On March 30, 2022, more than a majority in interest of our common shares by written consent approved such amendment to our Certificate of Incorporation. The Company expects to consummate this transaction May 30, 2022. We considered ASC Topic 470-50, Debt Modifications and Extinguishments in connection with the amendment of the interest rate and maturity date of the 2018 and 2019 Convertible Notes and determined that the modification would be considered a debt extinguishment. The unamortized discount of $1,092,295 at the date of amendment was recognized as a loss on debt extinguishment for the year ended November 30, 2020 On June 30, 2021, the Board of Directors of the Company, unanimously consented to amend its Articles of Incorporation to among other things authorize 29,432,320 shares of Preferred Stock, $0.001 par value. A majority of the Company’s stockholders have also approved the amendment to the Articles of Incorporation. The effectiveness of these Amendments are subject to the filing of an information statement with the US SEC and the State of Nevada.

PAYCHECK PROTECTION PROGRAM (PP

PAYCHECK PROTECTION PROGRAM (PPP) LOAN	12 Months Ended
	Nov. 30, 2021
RELATED PARTY TRANSACTIONS
PAYCHECK PROTECTION PROGRAM (PPP) LOAN	NOTE 9. PAYCHECK PROTECTION PROGRAM (PPP) LOAN On May 28, 2020, the Company obtained a Paycheck Protection Program (PPP) loan in the amount of $135,165. These business loans were established by the 2020 US Federal government Coronavirus Aid, Relief, and Economic Security Act (CARES Act) to help certain businesses, self-employed workers, sole proprietors, certain nonprofit organizations, and tribal businesses continue paying their workers. The CARES Act was established in order to enable small businesses to pay employees during the economic slowdown caused by COVID-19 by providing forgivable loans to qualifying businesses for up to 2.5 times their average monthly payroll costs. The amount borrowed under the CARES Act and used for payroll costs, rent, mortgage interest, and utility costs during the 24 week period after the date of loan disbursement is eligible to be forgiven provided that (a) we use the PPP Funds during the eight week period after receipt thereof, and (b) the PPP Funds are only used to cover payroll costs (including benefits), rent, mortgage interest, and utility costs. While the full loan amount may be forgiven, the amount of loan forgiveness will be reduced if, among other reasons, we do not maintain staffing or payroll levels or less than 60% of the loan proceeds are used for payroll costs. Principal and interest payments on any unforgiven portion of the PPP Funds will be deferred to the date the SBA remits the borrower’s loan forgiveness amount to the lender or, if the borrower does not apply for loan forgiveness, 10 months after the end of the borrower’s loan forgiveness period for six months and will accrue interest at a fixed annual rate of 1.0% and carry a two year maturity date. There is no prepayment penalty on the CARES Act Loan. On June 17, 2021, the Small Business Administration (SBA) approved the Company’s PPP loan forgiveness application for the full amount of $135,165.

NON-CONTROLLING INTEREST INVEST

NON-CONTROLLING INTEREST INVESTMENT IN BRAIN ARMOR, INC.	12 Months Ended
	Nov. 30, 2021
NON-CONTROLLING INTEREST INVESTMENT IN BRAIN ARMOR, INC.
NON-CONTROLLING INTEREST INVESTMENT IN BRAIN ARMOR, INC.	NOTE 10. NON-CONTROLLING INTEREST INVESTMENT IN BRAIN ARMOR, INC. On March 30, 2021, a non-US investor subscribed to the acquisition of 333,333 units of the Company’s Brain Armor Inc subsidiary. Each unit is comprised of one share of Brain Armor stock, $0.001 par value and a common stock purchase warrant evidencing the right to purchase one share of Common Stock, and was sold at a per unit price of USD $0.30 for an aggregate purchase price of USD $100,000 which was received by the Company on March 30, 2021. The vesting and exercise prices of the warrants are as follows: · 1/3 of shares shall be exercisable 6 months after the subscription date at an exercise price of $0.45 per share · 1/3 of shares shall be exercisable 12 months after the subscription date at an exercise price of $0.60 per share · 1/3 of shares shall be exercisable 18 months after the subscription date at an exercise price of $0.75 per share On May 5, 2021, a US investor subscribed to the acquisition of 3,333,333 units of the Company’s Brain Armor Inc subsidiary. Each unit is comprised of one share of Brain Armor stock, $0.001 par value and a common stock purchase warrant evidencing the right to purchase one share of Common Stock, and was sold at a per unit price of USD $0.30 for an aggregate purchase price of USD $1,000,000 of which $100,000 was received by the Company on May 13, 2021 and $100,000 on May 27, 2021. This subscription agreement has since been terminated. The vesting and exercise prices of the warrants are as follows: · 1/3 of shares shall be exercisable 6 months after the subscription date at an exercise price of $0.45 per share · 1/3 of shares shall be exercisable 12 months after the subscription date at an exercise price of $0.60 per share · 1/3 of shares shall be exercisable 18 months after the subscription date at an exercise price of $0.75 per share As a result of these transactions, the Company’s ownership was reduced to 70.5%.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Nov. 30, 2021
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES	NOTE 11. COMMITMENTS AND CONTINGENCIES Everlast License Agreement On December 23, 2013, the Company entered into a Deed of Assignment Agreement with Everlast World’s Boxing Headquarters Corporation, International Brand Management Limited, Sports Nutrition Products Incorporated and Manchester Capital Incorporated wherein Everlast, International Brand, Sports Nutrition and Manchester Capital are parties to a trade mark license and Sports Nutrition, a New York corporation, has assigned its interest in the trade mark license to the Company. Pursuant to the terms of the assignment agreement, Sports Nutrition Products Incorporated, a wholly owned subsidiary of Trident Brands Incorporated, assigned all of its rights, title, interest and benefit to the trade mark license to the Company effective December 23, 2013 and the Company assumed all of the obligations of Sports Nutrition Products Incorporated under the license agreement. The Company shall remain responsible to Everlast and International Brand for all acts and omissions of the subsidiary, Sports Nutrition Products Inc. The Everlast License Agreement includes a clause stating that Manchester Capital Incorporated will guarantee that the Licensee shall perform all of its obligations and duties under the License Agreement. If the Licensee defaults in the payment when due of any amount it is obliged to pay to Licensor under the License Agreement, or arising from its termination, Manchester Capital is unconditionally responsible to pay that amount to Licensor in the manner prescribed in the License Agreement as if it were the Licensee. The Royalty Calculation, as per the terms of the agreement, are as follows: In 2013, 7% of Net Retail Sales and 7% of 60% of Direct Response Sales Revenue; in 2014, 8% of Net Retail Sales and 8% of 60% of Direct Response Sales Revenue; in 2015, 9% of Net Retail Sales and 9% of 60% of Direct Response Sales Revenue; in 2016 onwards, 10% of Net Retail Sales and 10% of 60% of Direct Response Sales Revenue. The Annual Minimum Guaranteed Royalty is $120,000 in 2014, $235,000 in 2015, $320,000 in 2016, $345,000 in 2017 and in 2018 onwards, if the Agreement remains in force, will be 75% of the previous Year’s Royalty Calculation or the previous Year’s Annual Minimum Guaranteed Royalty plus 10%, whichever is greater. The agreement was terminated on December 31, 2017. On January 17, 2019, Everlast World’s Boxing Headquarters Corp. (“Everlast”) filed a counter civil lawsuit against the Company and other defendants. In that lawsuit, Everlast seeks payment from the defendants under a License Agreement dated June 4, 2013, for $425,555 in unpaid royalties allegedly due and owing under the License Agreement and interest on the allegedly unpaid royalties of $96,265, which interest allegedly continues to accrue. Everlast has also sought all costs, expenses, and legal fees incurred by Everlast in collecting monies that it claims are due under the License Agreement. On February 26, 2020, the court in the Everlast matter issued an Opinion and Order granting a motion to dismiss all of the Company’s claims against Everlast and granting a motion for judgment on the pleadings as to liability against the Company. The Court left open the question of damages to be awarded to Everlast. The Company had requested that the parties participate in settlement discussions before a magistrate judge or, in the alternative, that Everlast engage in limited discovery on these matters. No settlement was reached. On October 15, 2020, the Court in the Everlast case ordered, adjudged and decreed that Plaintiff Everlast have judgment and recover a total of $738,946 from the Company as follows: 1. $425,000 representing royalty payments due to Everlast; 2. Interest on royalty payments computed through October 15, 2020, in the sum of $242,920; 3. Costs and attorneys’ fees in the sum of $71,026 The Company has fully accrued the $738,946 liability as of November 30, 2021. On November 17, 2021, The Company entered Into a Stipulation of Settlement (“Settlement Agreement”) of the litigation captioned Everlast World’s Boxing Headquarters Corp. (“Everlast”) , Plaintiff vs. Trident Brands, Inc. and Manchester Capital Inc., Defendants, Case No. 21 Tj 90. Under the terms of the Settlement Agreement, the Company agreed to pay Everlast on or before February 15, 2022, the sum of $650,000 in full satisfaction of the Everlast’s judgment against the Company in the amount of $738,946. Under the Settlement Agreement, except for the first $250,000 of capital raised, the Company is required to pay Everlast 20% of the gross amount of any capital raising transaction, until the full $650,000 is paid, provided however that the full $650,000 was required to have been paid no later than February 15, 2022. The Company failed to pay Everlast the full $650,000 by February 15, 2022, as a result of which the Company is obligated to pay Everlast the judgment amount of $738,945, plus applicable interest (a total of $750,713 as of August 21, 2021) and attorney’s fees, less any payments made. Banc of America Leasing and Capital On December 1, 2020, Bank of America Leasing and Capital, LLC filed a legal action against the Company in the Superior Court for the State of California, County of San Mateo (Case NO. 20-CIV-05306), alleging breach of contract. The claim arises out of a software services contract between the Company and Oracle Corporation. Bank of America Leasing and Capital, LLC acquired Oracle’s rights under the agreement. The plaintiff claims the Company is liable for damages in the amount of $217,000 plus interests and costs. The Company has not filed an answer to this complaint. On February 22, 2021, the plaintiff requested that the Court enter a default judgment against the Company. The Company intends to engage counsel and defend against this claim. PIT Mycell On June 3, 2019, the Company filed a lawsuit against PIT Mycell, LLC, William E. Peterson III, New Age Ventures, LLC, Volker Berl, and Mycell Technologies, LLC (“Mycell”) in the Superior Court in Bergen County, New Jersey, Civil Action No. BER-L-004198-19, in which the Company seeks to require the defendants to perform under and allow the enforcement of certain notes made by Mycell and acquired by the Company in September 2017. The notes are past their stated maturity date of December 31, 2016. The Company also alleges that the parties had entered into a written Settlement Agreement Letter of Intent dated March 14, 2019 (the “Settlement”), but that the defendants repudiated it shortly thereafter. The notes had been the subject of an earlier lawsuit in Virginia in state court in Fairfax County between the Company and PIT Mycell, LLC that the Settlement was intended to resolve. The Company seeks to enforce the notes and the Settlement in the New Jersey lawsuit and requests actual damages in an amount to be proven at trial, attorneys’ fees and litigation costs, specific performance requiring certain defendants to enforce obligations under the notes against Mycell, specific performance requiring the defendants to execute a final Settlement Agreement consistent with the Settlement, an order permitting foreclosure on the collateral for the notes, and declaratory relief. On January 24, 2020, the New Jesey court denied Defendant’s Motions to dismiss the case. The parties have engaged in written discovery and exchanged productions of documents. Mycell filed for bankruptcy on November 25, 2020. The bankruptcy is completed and the Company no longer has a claim on the new company that has since emerged from bankruptcy. Contingencies The Company may be subject to various legal proceedings and claims that arise in the ordinary course of business. The Company records a liability when it is probable that a loss has been incurred and the amount is reasonably estimable. There is significant judgment required in both the probability determination and as to whether an exposure can be reasonably estimated. If any legal matter, that may arise, were resolved against the Company in a reporting period for amounts in excess of management’s expectations, the Company’s would reflect any potential claim in the consolidated financial statements for that reporting period.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Nov. 30, 2021
INCOME TAXES
INCOME TAXES	NOTE 12. INCOME TAXES Deferred tax assets consist of: As of November 30, 2021 As of November 30, 2020 Deferred tax assets: Net operating tax carryforwards $ 32,381,319 $ 29,295,465 Tax Rate 21 % 21 % Gross deferred tax assets 6,800,077 6,152,048 Valuation allowance (6,800,077 ) (6,152,048 ) Net deferred tax assets $ -0- $ -0- As of November 30, 2021, the Company has a net operating loss carryforward of approximately $32 million. Net operating loss carryforwards may now be carried forward indefinitely until the loss is fully recovered, but are limited to 80% of taxable income in any one tax period. Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carryforwards are expected to be available to reduce taxable income. As the achievement of required future taxable income is uncertain, the Company has recorded a valuation allowance. Tax years 2016 to 2020 are open to examination by federal and state taxing authorities. Due to the enactment of the Tax Reform Act of 2018, the corporate tax rate for those tax years beginning with 2018 was reduced to 21%.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Nov. 30, 2021
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS	NOTE 13. SUBSEQUENT EVENTS The Company failed to pay Everlast the full $650,000 by February 15, 2022, as per the November 17, 2021 Stipulation of Settlement with Everlast. The Company is now obligated to pay Everlast the judgment amount of $738,945, plus applicable interest (a total of $750,713 as of August 21, 2021) and attorney’s fees, less any payments made. Additionally, the litigation shall now proceed. The Board has authorized the following executive compensation to its executives: - Upon the closing of an initial financing (greater than $2,000,000) then the CEO shall be issued 1.5% of the fully diluted common stock and the Chairman shall receive 1.0% of the fully diluted common stock; - Upon the uplisting of the Company to the New York Stock Exchange (NYSE) or the Nasdaq (whether by merger or operations), then the CEO shall be issued 1.5% of the fully diluted common stock and the Chairman shall receive 1.0% of the fully diluted common stock; - Upon the closing of an acquisition, then the CEO shall be issued a bonus equal 3% of the total enterprise value of the deal and the Chairman shall receive 2% of the total enterprise value of the deal, which may at the option of the Company be paid in cash, or stock. If the bonus is paid in stock, then the stock shall be issued at a 20% discount to the market; WHEREAS Total Revenue* (in millions) Adjusted EBITDA* Exercise Price** Percent of Shares CEO *** Percent of Shares COO*** Percent of Shares CFO*** $ 1.00 N/A $ 0.05 1.00 % 0.25 % 0.25 % $ 2.00 N/A $ 0.125 1.00 % 0.25 % 0.25 % $ 4.00 N/A $ 0.25 1.00 % 0.25 % 0.25 % $ 8.00 $ 80,000 $ 0.50 1.00 % 0.25 % 0.25 % $ 12.00 $ 150,000 $ 0.75 1.00 % 0.25 % 0.25 % $ 18.00 $ 225,000 $ 1.00 1.00 % 0.25 % 0.25 % $ 30.00 $ 450,000 $ 1.50 1.00 % 0.25 % 0.25 % $ 45.00 $ 675,000 $ 2.50 1.00 % 0.25 % 0.25 % $ 75.00 $ 1,312,500 $ 5.00 1.00 % 0.25 % 0.25 % * Total Revenue shall be 75% of the share calculation and Adjusted EBITDA shall be 25% of the share calculation ** Exercise Price shall be the lower of the Exercise Price set forth above or a 20% discount to the 5-day VWAP ** Exercise Price shall not be adjusted accordingly for any stock splits, as these Exercise Prices are after giving effect to the split. *** Percent of Shares shall be based on the number of fully diluted common shares On March 3, 2022, the Board also authorized 4,000,000 shares to its employees. The shares will be vested immediately and issued all at once. On April 4, 2022, the Company announced that it filed an amendment to its certificate of incorporation to authorize 29,320,432 shares of Preferred Stock which it will use to satisfy approximately $17.7 Million of principal and accrued interest due under certain convertible notes, representing a conversion rate of $0.60 per share. The amendment authorizing the Preferred Shares was approved by a majority of the Company’s shareholders and was filed with the State of Nevada on March 31, 2022. The amendment is expected to be effective May 31, 2022.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Nov. 30, 2021
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Accounting	The Company’s financial statements are prepared using the accrual method of accounting. The Company has elected a November 30 year-end.
Use of Estimates and Assumptions	The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The ultimate impact from COVID-19 on the Company’s operations and financial results during 2021 and beyond will depend on, among other things, the ultimate severity and scope of the pandemic, the pace at which governmental and private travel restrictions and public concerns about public gatherings will ease, the rate at which historically large increases in unemployment rates will decrease, if at all, and whether, and the speed with which the economy recovers. We are not able to fully quantify the impact that these factors will have on our financial results in 2022 and beyond, but developments related to COVID-19 materially and adversely affected the Company’s financial performance in 2021.
Principal of Consolidation	The Company’s consolidated financial statements as of November 30, 2021 include the accounts of Trident Brands Incorporated and its subsidiaries: Brain Armor Inc. and Trident Brands Canada Ltd.
Earnings (Loss) Per Share	The Company follows the guidance in ASC No. 260, “Earnings Per Share”, which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. Basic net earnings (loss) per share amounts are computed by dividing the net earnings (loss) by the weighted average number of common shares outstanding. Due to net losses during the years ended November 30, 2021 and 2020, diluted earnings (loss) per share are the same as the basic earnings (loss) per share since inclusion of common stock equivalents would have been anti-dilutive.
Cash Equivalents	The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts receivables are recorded at their original invoice amounts. We regularly review collectability and establish an allowance for uncollectible amounts as necessary. As of November 30, 2021 and 2020, the Company’s accounts receivable was netted against an allowance of $160,210 and $155,186 respectively.
Inventory	Inventories are stated at the lower of cost or net realizable value. Cost is principally determined using the first-in, first-out (FIFO) method. We regularly review inventory for obsolete and slow-moving inventory and recognize a reserve or write offs as necessary. We recognized an inventory reserve of $401,606 and $195,264 as of November 30, 2021 and 2020, respectively. Inventory at November 30, 2021 consist of raw materials and finished goods of $842,076 and 39,848 respectively. Inventory at November 30, 2020 consist of raw materials and finished goods of $842,076 and $377,491, respectively.
Long-Lived Assets	We review our long-lived assets, including intangible assets subject to amortization, for recoverability whenever events or changes in circumstances indicate that the carrying amount of such long-lived asset or group of long-lived assets (collectively referred to as “the asset”) may not be recoverable. Such circumstances include, but are not limited to: · a significant decrease in the market price of the asset; · a significant change in the extent or manner in which the asset is being used; · a significant change in the business climate that could affect the value of the asset; · a current period loss combined with projection of continuing loss associated with use of the asset; and · a current expectation that, more likely than not, the asset will be sold or otherwise disposed of before the end of its previously estimated useful life. We continually evaluate whether such events and circumstances have occurred. When such events or circumstances exist, the recoverability of the asset’s carrying value shall be determined by estimating the undiscounted future cash flows (cash inflows less associated cash outflows) that are directly associated with and that are expected to arise as a direct result of the use and eventual disposition of the asset.
Intangible Assets	Intangible assets have either an identifiable or indefinite useful life. Intangible assets with identifiable useful lives are amortized on a straight-line basis over their economic or legal life, whichever is shorter. The Company currently does not have any amortizable intangible assets. The Company’s indefinite-lived intangible assets consist of trademarks. The Company reviews its indefinite-lived intangible assets for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. Impairment losses are recognized only if the carrying amount exceeds its fair value.
Beneficial Conversion Features	The intrinsic value of a beneficial conversion feature inherent to a convertible note payable, which is not bifurcated and accounted for separately from the convertible note payable and may not be settled in cash upon conversion, is treated as a discount to the convertible note payable. This discount is amortized over the period from the date of issuance to the date the note is due using the effective interest method. If the note payable is retired prior to the end of its contractual term, the unamortized discount is expensed in the period of retirement to interest expense. In general, the beneficial conversion feature is measured by comparing the effective conversion price, after considering the relative fair value of detachable instruments included in the financing transaction, if any, to the fair value of the common shares at the commitment date to be received upon conversion.
Fair Value of Financial Instruments	The Company measures its financial assets and liabilities in accordance with the requirements of FASB ASC 820, “Fair Value Measurements and Disclosures”. ASC 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows: Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed equities. Level 2 - Pricing inputs are other than quoted prices in active markets included in level 1, which are either directly or indirectly observable as of the reported date and includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors, and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options and collars. Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value. The carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash and cash equivalents, accounts receivable, accounts payable and note payable. The fair value of the Company’s long-term debt is estimated based on current rates that would be available for debt of similar terms which is not significantly different from its stated value. As of November 30, 2021 the Company did not have any financial assets or liabilities measured and recorded at fair value on the Company’s consolidated balance sheets on a recurring basis, except for a derivative liability, related to the embedded conversion option on the 2016 and 2018 convertible notes, with a fair value of $0 as of November 30, 2021 and 2020. The derivative liability was fair valued using Level 3 inputs. The following table provides a summary of the changes in fair value, including net transfers in and/or out, of the derivative financial instruments, measured at fair value on a recurring basis using significant unobservable inputs: Balance at November 30, 2019 5,825,480 Unrealized derivative gain included in other expense (4,312,338 ) APIC reclassified to derivative liability 3,981,221 Resolution of derivative liability (5,494,363 ) Balance at November 30, 2020 and 2021 $ -0- The fair value of the derivative liabilities are calculated at the time of issuance and the Company records a derivative liability for the calculated value. Changes in the fair value of the derivative liabilities are recorded in other income (expense) in the consolidated statements of operations. The following are the assumptions used for derivative instruments valued using the Black Scholes option pricing model as of November 30, 2021 and November 30, 2020: 2021 2020 Market value of stock on measurement date $ N/A $ 0.033 Risk-fee interest rate N/A 0.16% and 0.18 % Dividend yield N/A 0 % Volatility factor N/A 173.23 % Term. N/A 0.085 and 1.0 yrs
Derivative Financial Instruments	Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments and measurement of their fair value for accounting purposes. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt under ASC 470, the Company will continue its evaluation process of these instruments as derivative financial instruments under ASC 815. The Company applies the guidance in ASC 815-40-35-12 to determine the order in which each convertible instrument would be evaluated for derivative classification. The Company’s sequencing policy is to evaluate for reclassification contracts with the earliest inception date first.
Revenue	The Company markets a range of branded consumer products in the active nutrition and dietary supplement categories under the Brain Armor® label. Four customers accounted for 18.9%, 16.8%, 14.4% and 12.4% of total revenue, compared to four customers for 22.3%, 17.7%, 13.0% and 10.2% in the prior year. One customer accounted for 10.9% of total accounts receivable, compared to three customers for 16.9%, 15.9% and 11.9% in the prior year. The Company records revenue when all of the following criteria are met: 1) the contract with a customer is identified, 2) the performance obligations in the contract are identified, 3) the transaction price is determined, 4) the transaction price has been allocated to the performance obligations and 5) when each performance obligation is satisfied. Customer returns, allowances and consideration paid to customers for services which are not considered distinct are recorded as reductions to revenues.
Cost of Sales	Cost of sales includes the direct purchase cost of the product based on the FIFO method. The Company purchased 100% of its products from one vendor for the year ended November 30, 2021 and three vendors provided 97% of the Company’s products for the year ended November 30, 2020.
Stock-Based Compensation	The Company accounts for employee and non-employee stock-based compensation in accordance with ASC-718, “Compensation-Stock Compensation”. ASC-718 requires companies to measure the cost of employee services received in exchange for an award of equity instruments, including stock options, based on the grant-date fair value of the award and to recognize it as compensation expense over the period the employee is required to provide service in exchange for the award, usually the vesting period.
Income Taxes	Income taxes are provided in accordance with ASC No. 740, Accounting for Income Taxes. A deferred tax asset or liability is recorded for all temporary differences between financial and tax reporting and net operating loss carryforwards. Deferred tax expense (benefit) results from the net change during the year of deferred tax assets and liabilities. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion of all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The Company includes interest and penalties arising from the underpayment of income taxes in the statements of operation in the provision for income taxes. As of November 30, 2021 and 2020, the Company had no accrued interest or penalties related to uncertain tax positions.
Related Parties	A party is considered to be related to the Company if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests is also a related party. On October 15, 2021, a Promissory Note was issued to Anthony Pallante, Chairman and a significant stockholder of the Company. The Note is unsecured and was issued in consideration for payments made to creditors in satisfaction of Company obligations. Mr. Pallante loaned the Company $20,101. The Note bears Interest at a rate of 8% per annum. All unpaid principal and accrued interest shall be due and payable upon demand at any time subsequent to six (6) months from the date the notes were issued. As of November 30, 2021, Mr. Pallante made additional payments of $16,731 for a total of $36,832.
Recent Accounting Pronouncements	The Company has evaluated the following recent accounting pronouncements through the date the financial statements were issued and filed with the Securities and Exchange Commission and believe that none of them will have a material effect on the Company’s financial statements: In July 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. For all other entities, the amendments in Part I of this Update are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. Management’s evaluation was that there was no impact to the Company’s consolidated financial statements. In December 2018, the FASB issued ASC 842 and as ASU 2016-02, is the new lease accounting standard published by the Financial Accounting Standards Board (FASB). It replaced the previous US GAAP leasing standard, ASC 840. The purpose of the new standard is to close a major accounting loophole in ASC 840: off-balance sheet operating leases. Public companies began to implement the standard starting after December 15, 2018. Private companies will follow a year later on December 15, 2020. ASC 842 represents a significant overhaul of the accounting treatment for leases, with the most significant change being that most leases, including most operating leases, are now capitalized on the balance sheet. Under ASC 840, FASB permitted operating leases to be reported only in the footnotes of corporate financial statements. Under ASC 842, the only leases that are exempt from the capitalization requirement are short-term leases less than or equal to 12 months in length. This became effective December 1, 2019 and the Company chose to adopt it early on December 1, 2018. The adoption did not have any material impact on the Company’s consolidated financial statements as the Company has no long term leases. On June 20, 2018, the FASB issued ASU 2018-07, Improvements to Nonemployee Share-Based Payment Accounting, as part of its ongoing Simplification Initiative. Currently, share-based payments to nonemployees are accounted for under Subtopic 505-50 which significantly differs from the guidance for share-based payments to employees under Topic 718. This ASU supersedes Subtopic 505-50 by expanding the scope of Topic 718 to include nonemployee awards and generally aligning the accounting for nonemployee awards with the accounting for employee awards (with limited exceptions). The effective date is for fiscal years beginning after December 15, 2018. The Company adopted the measure on December 1, 2019. The adoption did not have any material impact on the Company’s consolidated financial statements.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Nov. 30, 2021
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Schedule of change in fair value of financial instruments	Balance at November 30, 2019 5,825,480 Unrealized derivative gain included in other expense (4,312,338 ) APIC reclassified to derivative liability 3,981,221 Resolution of derivative liability (5,494,363 ) Balance at November 30, 2020 and 2021 $ -0-
Schedule of derivative instruments valued using the Black Scholes option pricing model	2021 2020 Market value of stock on measurement date $ N/A $ 0.033 Risk-fee interest rate N/A 0.16% and 0.18 % Dividend yield N/A 0 % Volatility factor N/A 173.23 % Term. N/A 0.085 and 1.0 yrs

WARRANTS AND OPTIONS (Tables)

WARRANTS AND OPTIONS (Tables)	12 Months Ended
	Nov. 30, 2021
WARRANTS AND OPTIONS (Tables)
Schedule of stock option activity	Number of Options Weighted Average Exercise Price Contractual Life in Years Intrinsic Value Outstanding - November 30, 2019 3,215,000 $ .40 2.42 $ -0- Exercisable - November 30, 2019 3,215,000 $ .40 2.42 Granted -0- Exercised or Vested -0- Forfeited or Expired 1,382,500 Outstanding – November 30, 2020 1,832,500 $ 0.40 2.02 Exercisable - November 30, 2020 1,832,500 $ 0.40 2.02 -0- Granted -0- Exercised or Vested -0- Forfeited or Expired 300,000 Outstanding - November 30, 2021 1,532,500 $ 0.40 1.02 Exercisable - November 30, 2021 1,532,500 $ 0.40 1.02 -0-

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Nov. 30, 2021
INCOME TAXES
Schedule of deferred tax assets	As of November 30, 2021 As of November 30, 2020 Deferred tax assets: Net operating tax carryforwards $ 32,381,319 $ 29,295,465 Tax Rate 21 % 21 % Gross deferred tax assets 6,800,077 6,152,048 Valuation allowance (6,800,077 ) (6,152,048 ) Net deferred tax assets $ -0- $ -0-

SUBSEQUENT EVENTS (Tables)

SUBSEQUENT EVENTS (Tables)	12 Months Ended
	Nov. 30, 2021
SUBSEQUENT EVENTS
Schedule of ubsequent events	Total Revenue* (in millions) Adjusted EBITDA* Exercise Price** Percent of Shares CEO *** Percent of Shares COO*** Percent of Shares CFO*** $ 1.00 N/A $ 0.05 1.00 % 0.25 % 0.25 % $ 2.00 N/A $ 0.125 1.00 % 0.25 % 0.25 % $ 4.00 N/A $ 0.25 1.00 % 0.25 % 0.25 % $ 8.00 $ 80,000 $ 0.50 1.00 % 0.25 % 0.25 % $ 12.00 $ 150,000 $ 0.75 1.00 % 0.25 % 0.25 % $ 18.00 $ 225,000 $ 1.00 1.00 % 0.25 % 0.25 % $ 30.00 $ 450,000 $ 1.50 1.00 % 0.25 % 0.25 % $ 45.00 $ 675,000 $ 2.50 1.00 % 0.25 % 0.25 % $ 75.00 $ 1,312,500 $ 5.00 1.00 % 0.25 % 0.25 %

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	12 Months Ended
	Nov. 30, 2021	Nov. 30, 2020
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Beginning balance	$ 0	$ 5,825,480
Derivative (gain)/loss		(4,312,338)
APIC reclassified to derivative liability	$ 3,981,221	3,981,221
Resolution of derivative liability		(5,494,363)
Ending balance		$ 0

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) - Black Scholes option pricing model [Member]	12 Months Ended
	Nov. 30, 2020$ / shares
Market value of stock on measurement date	$ 0.033
Divident yield	0.00%
Volatility factor	173.23%
Minimum [Member]
Risk-fee interest rate	0.16%
Term	1 month
Maximum [Member]
Risk-fee interest rate	0.18%
Term	1 year

SUMMARY OF SIGNIFICANT ACCOUN_6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	Oct. 15, 2021	Nov. 30, 2021	Nov. 30, 2020
Loan amount	$ 20,101
Note bears Interest rate	8.00%
Allowance for Accounts Receivable		$ 160,210	$ 155,186
Additional loan payment	$ 16,731
Fair value of convertible note	$ 36,832	0	0
Inventory reserve		401,606	195,264
Inventory		881,924	1,219,567
Finished Goods [Member]
Inventory		39,848	377,491
Raw Materials [Member]
Inventory		$ 842,076	$ 842,076
Accounts Receivable [Member] | Customer Three [Member]
Concentration risk percentage		11.90%	18.90%
Accounts Receivable [Member] | Customer One [Member]
Concentration risk percentage		16.90%
Accounts Receivable [Member] | Customer Two [Member]
Concentration risk percentage		15.90%
Sales Revenue, Goods, Net [Member] | Customer Three [Member]
Concentration risk percentage		13.00%	14.40%
Sales Revenue, Goods, Net [Member] | Customer Four [Member]
Concentration risk percentage		10.20%	16.80%
Sales Revenue, Goods, Net [Member] | Customer One [Member]
Concentration risk percentage		22.30%	12.40%
Sales Revenue, Goods, Net [Member] | Customer Two [Member]
Concentration risk percentage		17.70%	10.90%
Cost Of Goods Services [Member] | Supplier Concentration Risk One [Member]
Concentration risk percentage		97.00%

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative)	Nov. 30, 2021USD ($)
GOING CONCERN
Cash	$ 7,653
Working capital deficit	$ (8,869,959)

NOTE RECEIVABLE (Details Narrat

NOTE RECEIVABLE (Details Narrative) - USD ($)	Sep. 12, 2017	Nov. 30, 2021	Nov. 30, 2020	Nov. 30, 2018
Provision for note receivable and accrued interest		$ 5,024	$ 99,207
Note Purchase Agreement [Member] | Mycell Technologies Llc [Member] | Fengate Trident LP [Member]
Common stock issued for purchase of secured convertible promissory notes (in shares)	811,887
Provision for note receivable and accrued interest		$ 617,010	$ 617,010
Principal amount payable	$ 511,141
Interest amount	$ 94,526			$ 105,869

INTANGIBLE ASSETS (Details Narr

INTANGIBLE ASSETS (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Dec. 22, 2017	Nov. 30, 2021	Nov. 30, 2020
Intangible Assets, net		$ 0	$ 400,000
Impairment Loss		400,000	$ 0
Omega-3 oil [Member] | Licensing Agreements [Member]
Outstandig amount of intellectual property		79,040
Payment for intellectual property	$ 400,000	$ 200,000
Intangible assets payment description		the Company agreed to meet certain conditions, that when satisfied will have an equivalent value of $400,000. The costs incurred to meet these conditions are being charged to intangible assets.

WARRANTS AND OPTIONS (Details)

WARRANTS AND OPTIONS (Details) - Stock Options [Member] - USD ($)	12 Months Ended
	Nov. 30, 2021	Nov. 30, 2020
Number of Options
Outstanding, Beginning Balance	1,832,500	3,215,000
Exercisable, Beginning Balance	1,832,500	3,215,000
Granted	0	0
Exercised or Vested	0	0
Forfeited or Expired	300,000	1,382,500
Outstanding, Ending Balance	1,532,500	1,532,500
Exercisable, Ending Balance	1,532,500	1,832,500
Weighted Average Exercise Price
Weighted Average Exercise Price, Outstanding, Begnning Balance	$ 0.40	$ 0.40
Weighted Average Exercise Price, Exercisable, Begnning Balance	0.40	0.40
Weighted Average Exercise Price, Outstanding, Ending Balance	0.40	0.40
Weighted Average Exercise Price, Exercisable, ending Balance	$ 0.40	$ 0.40
Contractual Life in Years
Outstanding Contractual Life in Years, Beginning Balance	2 years 7 days	2 years 5 months 1 day
Exercisable Contractual Life in Years, Beginning Balance	2 years 7 days	2 years 5 months 1 day
Outstanding Contractual Life in Years, Ending Balance	1 year 7 days	2 years 7 days
Exercisable Contractual Life in Years, Ending Balance	1 year 7 days	2 years 7 days
Intrinsic Value
Exercisable Intrinsic Value, Beginning Balance	$ 0	$ 0
Exercisable Intrinsic Value, Ending Balance	$ 0	$ 0

WARRANTS AND OPTIONS (Details N

WARRANTS AND OPTIONS (Details Narrative) - USD ($)	Jan. 04, 2019	Dec. 06, 2017	Nov. 30, 2021	Nov. 30, 2020	May 05, 2019
Stock option vested		1,307,500
Outstanding stock options			1,832,500
Remaining stock option vested		$ 1,307,500
Stock options exercise period		5 years
Exercise price (in dollars per share)		$ 0.85
Outstanding stock options exercise price (in dollars per share)		$ 1
Stock options expense			$ 0	$ 8,875
Compensation expense			$ 0
Options granted	$ 0.40
Extended option expiration date			May 5, 2020
Board of Directors [Member]
Stock options shares issued					750,000
Stock options shares outstanding					750,000
Stock Options [Member] | 2013 [Member]
Issuance of stock option to employee description			The 2013 Stock Option Plan authorizes the Company to issue incentive and non-qualified stock options to employees and consultants of the Company to purchase a number of shares not to exceed 15% of the Company’s currently issued and outstanding securities.
Maximum [Member]
Stock options exercise period		5 years
Stock options to purchase common shares		2,615,000

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - Mr. Pallante [Member] - USD ($)	Oct. 15, 2021	Nov. 30, 2021
Additional payment of loan		$ 16,731
Due to related party	$ 20,101
Total loan		$ 36,832
Debt instrument interest rate	8.00%

CONVERTIBLE DEBT (Details Narra

CONVERTIBLE DEBT (Details Narrative) - USD ($)

May 09, 2017

May 14, 2015

Feb. 05, 2015

Jun. 03, 2020

Jan. 09, 2020

Sep. 30, 2019

May 16, 2018

Nov. 30, 2017

Sep. 26, 2016

Jan. 29, 2015

Nov. 30, 2021

Nov. 30, 2020

Apr. 01, 2022

Mar. 31, 2022

Jun. 30, 2021

Mar. 05, 2020

Nov. 30, 2018

APIC reclassified to derivative liability

$ 3,981,221

$ 3,981,221

Increased tranche amount

$ 936,168

Embedded conversion

5,494,363

Beneficial conversion feature

$ 647,888

Amortized for prior year

855,987

Preferred stock, shares

29,320,432

29,432,320

Preferred stock shares, amount

$ 17,659,392

Price per share

$ 0.60

Debt extinguisment

$ 1,092,295

Conversion, description

all amounts owing under the 2016 Convertible Notes through November 30, 2021 (including accrued interest thereon) and (ii) all accrued interest on the 2018 and 2019 Convertible Notes through November 30, 2021. The conversion is expected to occur by the end of June, 2021. The 2018 and 2019 Convertible Notes were further amended to (i) eliminate the conversion feature of such notes, (ii) provide for a simple interest rate of 8% per annum, with the first 2 years of interest payable at maturity of the 2018 and 2019 Convertible Notes and the last three years of interest payable quarterly beginning February 28, 2023; and (iii) extend the maturity of such notes until November 30, 2025.

Extended maturity date

Dec. 1, 2021

Sep. 30, 2019

Proceeds from convertible debt

$ 0

936,168

Amortization of debt discount

0

1,885,587

Conversion price (in dollars per share)

$ 0.60

November 6, 2019 [Member] | Third Tranche [Member]

Proceeds from convertible debt

3,795,033

Interest payment

936,168

November 30, 2018 [Member] | First Tranche [Member]

Proceeds from promissory note

3,400,780

April 13, 2019 [Member] | Second Tranche [Member]

Proceeds from promissory note

2,804,187

Convertible Debt [Member] | Minimum [Member]

Bearing interest rate

6.00%

Convertible Debt [Member] | Maximum [Member]

Bearing interest rate

8.00%

Securities Purchase Agreement [Member] | Convertible Debt [Member]

Proceeds from convertible debt

$ 4,100,000

Amortization of debt discount

3,333,334

Intrinsic value of notes

3,333,334

Principal amount of debt

$ 2,300,000

Common stock conversion, shares

16,666,667

3,239,437

Bearing interest rate

8.00%

6.00%

Interest amortized

$ 334,988

Proceeds from promissory note

$ 4,100,000

Additional funding amount

5,900,000

Aggregate amount of promissory note

10,000,000

Conversion price (in dollars per share)

$ 0.60

$ 0.71

2016 Notes [Member]

Extended maturity date

Dec. 31, 2020

Proceeds from convertible debt

$ 4,400,000

$ 500,000

$ 1,800,000

$ 1,500,000

$ 4,100,000

Terms of amendment, description

Pursuant to the Amendment, Fengate has agreed to convert all of the 2016 Notes on or before the earlier to occur of (i) the maturity date of the 2016 Convertible Notes and (ii) the Company raising new equity investment of not less than US$2,000,000, on terms mutually acceptable to Fengate and the Company (subject to Fengate’s regulatory considerations). Conversion of the 2016 Notes will occur in a single conversion transaction at a price that is equal to a 25% discount to the average closing price of the Company’s common stock for the 10 trading days immediately prior to the conversion date, with the exact structure of the conversion to be determined by the parties. On June 3, 2020 the maturity date was extended from May 31 to December 31, 2020.

2016 Notes [Member] | February 5, 2015 [Member]

Convertible promissory notes

$ 1,800,000

2016 Notes [Member] | May 14, 2015 [Member]

Convertible promissory notes

500,000

2016 Notes [Member] | May 9, 2017 [Member]

Convertible promissory notes

4,400,000

2016 Notes [Member] | May 16, 2018 [Member]

Convertible promissory notes

1,500,000

2018 Convertible Note [Member] | Conversion Option [Member] | Re-value [Member]

Conversion option, description

The assumptions used were a discount rate of 2.80%, 1.96% and 1.96%; volatility rate of 79.57%, 104.70% and 107.3%; and a term of 1.50, 1.13 and 0.57 years respectively

Unamortized debt discount

$ 0

Amortization of debt

1,885,587

$ 1,857,295

2018 Convertible Note [Member] | Conversion Option [Member] | November 30, 2018 [Member]

Black scholes model conversion option

892,000

2018 Convertible Note [Member] | Conversion Option [Member] | April 13, 2019 [Member]

Black scholes model conversion option

$ 1,911,256

2018 Convertible Note [Member] | Conversion Option [Member] | Range One [Member]

Term

1 year 6 months

Volatility

79.57%

Discount rate

2.80%

Black scholes model conversion option

$ 1,696,933

2018 Convertible Note [Member] | Conversion Option [Member] | Range Two [Member]

Term

1 year 1 month 17 days

Volatility

104.70%

Discount rate

1.96%

2018 Convertible Note [Member] | Conversion Option [Member] | Range Three [Member]

Term

6 months 25 days

Volatility

107.30%

Discount rate

1.96%

2018 Convertible Note [Member] | Securities Purchase Agreement [Member]

Principal amount of debt

$ 10,000,000

Bearing interest rate

12.00%

Convertible note description

Company at a 25% discount to the average closing price of the common shares during the 10 trading days immediately prior to the applicable conversion date

Director [Member]

Price per share

$ 0.001

Preferred stock, shares authorized

29,432,320

29,432,320

Black-Scholes Model [Member]

Beneficial conversion feature

$ 7,965,083

Term

4 months 20 days

Discount rate

1.96%

Volatility rate

148.80%

PAYCHECK PROTECTION PROGRAM (_2

PAYCHECK PROTECTION PROGRAM (PPP) LOAN (Details Narrative) - Paycheck Protection Program [Member] - USD ($)	1 Months Ended
	May 28, 2020	Jun. 17, 2021
Description of forgivable loans	The CARES Act was established in order to enable small businesses to pay employees during the economic slowdown caused by COVID-19 by providing forgivable loans to qualifying businesses for up to 2.5 times their average monthly payroll costs. The amount borrowed under the CARES Act and used for payroll costs, rent, mortgage interest, and utility costs during the 24 week period after the date of loan disbursement is eligible to be forgiven provided that (a) we use the PPP Funds during the eight week period after receipt thereof, and (b) the PPP Funds are only used to cover payroll costs (including benefits), rent, mortgage interest, and utility costs. While the full loan amount may be forgiven, the amount of loan forgiveness will be reduced if, among other reasons, we do not maintain staffing or payroll levels or less than 60% of the loan proceeds are used for payroll costs. Principal and interest payments on any unforgiven portion of the PPP Funds will be deferred to the date the SBA remits the borrower’s loan forgiveness amount to the lender or, if the borrower does not apply for loan forgiveness, 10 months after the end of the borrower’s loan forgiveness period for six months and will accrue interest at a fixed annual rate of 1.0% and carry a two year maturity date. There is no prepayment penalty on the CARES Act Loan.
PPP Loan Payable	$ 135,165	$ 135,165

NONCONTROLLING INTEREST INVESTM

NONCONTROLLING INTEREST INVESTMENT IN BRAIN ARMOR INC (Details Narrative) - Brain Armor Inc [Member] - USD ($)	May 13, 2021	May 05, 2021	May 27, 2021	Mar. 30, 2021
Purchase price	$ 100,000	$ 1,000,000	$ 100,000	$ 100,000
Per unit price		$ 0.30		$ 0.30
Number of shares acquired		3,333,333		333,333
Par value		$ 0.001		$ 0.001
Exercisable after 12 months [Member]
One third warrant exercise price		0.60		0.60
Exercisable after 18 months [Member]
One third warrant exercise price		0.75		0.75
Subscription Arrangement [Member]
One third warrant exercise price		$ 0.45		$ 0.45

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	Oct. 15, 2020	Aug. 21, 2021	Dec. 02, 2020	Nov. 30, 2021	Feb. 15, 2022	Nov. 17, 2021	Nov. 30, 2017	Nov. 30, 2016	Nov. 30, 2015	Nov. 30, 2014
Agreement to payment						$ 650,000
Judgment amount of agreement						738,946
Capital raised payment						250,000
Transaction full payment						$ 650,000
Payment for full payment of everlast					$ 650,000
Payment for everlast judgment amount					738,945
Attorney's fees, less payments					$ 750,713
Annual Minimum Guaranteed Royalty							$ 345,000	$ 320,000	$ 235,000	$ 120,000
Description of annual minimum guaranteed royalty				in 2018 onwards, if the Agreement remains in force, will be 75% of the previous Year’s Royalty Calculation or the previous Year’s Annual Minimum Guaranteed Royalty plus 10%, whichever is greater.
Cost and attorney's fees		$ 738,945
Plantiff [Member]
Recovery, amount	$ 738,946
Payment due	425,000
Ineterest royalty payment	242,920
Cost and attorney's fees	$ 71,026
Accrued liability				$ 738,946
Cost for damages			$ 217,000
License Agreement [Member] | June 4, 2013 [Member]
Payment of unpaid royalties				425,555
Payment of unpaid interest				$ 96,265
Royalty Calculation Year 2013 [Member]
Percentage of net retail sales				7.00%
Percentage of direct response sales revenue				7% of 60%
Royalty Calculation Year 2014 [Member]
Percentage of net retail sales				8.00%
Percentage of direct response sales revenue				8% of 60%
Royalty Calculation Year 2015 [Member]
Percentage of net retail sales				9.00%
Percentage of direct response sales revenue				9% of 60%
Royalty Calculation Year 2016 [Member]
Percentage of net retail sales				10.00%
Percentage of direct response sales revenue				10% of 60%

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	12 Months Ended
	Nov. 30, 2021	Nov. 30, 2020
INCOME TAXES
Net operating tax carryforwards	$ 32,381,319	$ 29,295,465
Tax rate	21.00%	21.00%
Gross deferred tax assets	$ 6,800,077	$ 6,152,048
Valuation allowance	(6,800,077)	(6,152,048)
Net deferred tax assets	$ 0	$ 0

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	12 Months Ended
	Nov. 30, 2021	Nov. 30, 2020
Corporate income tax rate effective in 2018	21.00%
Net operating loss carryforwards	$ 32,381,319	$ 29,295,465
Operating Income (Loss) [Member]
Corporate income tax rate effective in 2018	80.00%
Net operating loss carryforwards	$ 32,000,000

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - USD ($)	1 Months Ended	12 Months Ended
	Feb. 15, 2022	Nov. 30, 2021	Nov. 30, 2020
Percent of Shares CEO	1.00%
Total Revenue		$ 224,720	$ 872,923
Exercise Price Range Three [Member] | Subsequent Event [Member]
Percent of Shares CEO	1.00%
Total Revenue	$ 4,000,000
Exercise Price	$ 0.25
Percent of Shares COO	0.25%
Percent of Shares CFO	0.25%
Exercise Price Range Two [Member] | Subsequent Event [Member]
Percent of Shares CEO	1.00%
Total Revenue	$ 2,000,000
Exercise Price	$ 0.125
Percent of Shares COO	0.25%
Percent of Shares CFO	0.25%
Exercise Price Range Four [Member] | Subsequent Event [Member]
Percent of Shares CEO	1.00%
Total Revenue	$ 8,000,000
Exercise Price	$ 0.50
Percent of Shares COO	0.25%
Percent of Shares CFO	0.25%
Adjusted EBITDA	$ 80,000
Exercise Price Range Five [Member] | Subsequent Event [Member]
Percent of Shares CEO	1.00%
Total Revenue	$ 12,000,000
Exercise Price	$ 0.75
Percent of Shares COO	0.25%
Percent of Shares CFO	0.25%
Adjusted EBITDA	$ 150,000
Exercise Price Range Six [Member] | Subsequent Event [Member]
Percent of Shares CEO	1.00%
Total Revenue	$ 18,000,000
Exercise Price	$ 1
Percent of Shares COO	0.25%
Percent of Shares CFO	0.25%
Adjusted EBITDA	$ 225,000
Exercise Price Range Seven [Member] | Subsequent Event [Member]
Percent of Shares CEO	1.00%
Total Revenue	$ 30,000,000
Exercise Price	$ 1.50
Percent of Shares COO	0.25%
Percent of Shares CFO	0.25%
Adjusted EBITDA	$ 450,000
Exercise Price Range Eight [Member] | Subsequent Event [Member]
Percent of Shares CEO	1.00%
Total Revenue	$ 45,000,000
Exercise Price	$ 2.50
Percent of Shares COO	0.25%
Percent of Shares CFO	0.25%
Adjusted EBITDA	$ 675,000
Exercise Price Range Nine [Member] | Subsequent Event [Member]
Percent of Shares CEO	1.00%
Total Revenue	$ 75,000,000
Exercise Price	$ 5
Percent of Shares COO	0.25%
Percent of Shares CFO	0.25%
Adjusted EBITDA	$ 1,312,500
Exercise Price Range One [Member] | Subsequent Event [Member]
Percent of Shares CEO	1.00%
Total Revenue	$ 1,000,000
Exercise Price	$ 0.05
Percent of Shares COO	0.25%
Percent of Shares CFO	0.25%

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	1 Months Ended
	Feb. 15, 2022	Aug. 21, 2021	Apr. 01, 2022	Jun. 30, 2021
SUBSEQUENT EVENTS
Preferred stock, shares			29,320,432	29,432,320
Failed to pay Everlast the full amount	$ 650,000
Amount of litigation expense		$ 738,945
Litigation Interest		$ 750,713
Principal and accrued interest			$ 17,700,000
Conversion price (in dollars per share)			$ 0.60
Authorized shares to employees	4,000,000